Estradiol valerate/medroxyprogesterone triphasic

Drug Profile

Estradiol valerate/medroxyprogesterone triphasic

Alternative Names: Diviseq; Estradiol valerate + medroxyprogesterone acetate - Orion Pharma

Latest Information Update: 09 Mar 2015

Price : $50

At a glance

  • Originator Orion
  • Developer HRA Pharma; Orion
  • Class Estradiol congeners; Estrenes; Hormonal replacements; Pregnenediones
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Menopausal syndrome

Most Recent Events

  • 21 Oct 2003 Launched for Menopausal syndrome in Russia (PO)
  • 17 Oct 2003 Launched for Menopausal syndrome in South Korea (PO)
  • 17 Oct 2003 Launched for Menopausal syndrome in Lithuania (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top